Tags

Type your tag names separated by a space and hit enter

The basis of a more contagious 501Y.V1 variant of SARS-COV-2.
bioRxiv. 2021 Feb 02B

Abstract

Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) is causing a world-wide pandemic. A variant of SARS-COV-2 (20I/501Y.V1) recently discovered in the United Kingdom has a single mutation from N501 to Y501 within the receptor binding domain (Y501-RBD), of the Spike protein of the virus. This variant is much more contagious than the original version (N501-RBD). We found that this mutated version of RBD binds to human Angiotensin Converting Enzyme 2 (ACE2) a ~10 times more tightly than the native version (N501-RBD). Modeling analysis showed that the N501Y mutation would allow a potential aromatic ring-ring interaction and an additional hydrogen bond between the RBD and ACE2. However, sera from individuals immunized with the Pfizer-BioNTech vaccine still efficiently block the binding of Y501-RBD to ACE2 though with a slight compromised manner by comparison with their ability to inhibit binding to ACE2 of N501-RBD. This may raise the concern whether therapeutic anti-RBD antibodies used to treat COVID-19 patients are still efficacious. Nevertheless, a therapeutic antibody, Bamlanivimab, still binds to the Y501-RBD as efficiently as its binds to N501-RBD.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Preprint

Language

eng

PubMed ID

33564771

Citation

Liu, Haolin, et al. "The Basis of a More Contagious 501Y.V1 Variant of SARS-COV-2." BioRxiv : the Preprint Server for Biology, 2021.
Liu H, Zhang Q, Wei P, et al. The basis of a more contagious 501Y.V1 variant of SARS-COV-2. bioRxiv. 2021.
Liu, H., Zhang, Q., Wei, P., Chen, Z., Aviszus, K., Yang, J., Downing, W., Peterson, S., Jiang, C., Liang, B., Reynoso, L., Downey, G. P., Frankel, S. K., Kappler, J., Marrack, P., & Zhang, G. (2021). The basis of a more contagious 501Y.V1 variant of SARS-COV-2. BioRxiv : the Preprint Server for Biology. https://doi.org/10.1101/2021.02.02.428884
Liu H, et al. The Basis of a More Contagious 501Y.V1 Variant of SARS-COV-2. bioRxiv. 2021 Feb 2; PubMed PMID: 33564771.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The basis of a more contagious 501Y.V1 variant of SARS-COV-2. AU - Liu,Haolin, AU - Zhang,Qianqian, AU - Wei,Pengcheng, AU - Chen,Zhongzhou, AU - Aviszus,Katja, AU - Yang,John, AU - Downing,Walter, AU - Peterson,Shelley, AU - Jiang,Chengyu, AU - Liang,Bo, AU - Reynoso,Lyndon, AU - Downey,Gregory P, AU - Frankel,Stephen K, AU - Kappler,John, AU - Marrack,Philippa, AU - Zhang,Gongyi, Y1 - 2021/02/02/ PY - 2021/2/10/entrez PY - 2021/2/11/pubmed PY - 2021/2/11/medline JF - bioRxiv : the preprint server for biology JO - bioRxiv N2 - Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) is causing a world-wide pandemic. A variant of SARS-COV-2 (20I/501Y.V1) recently discovered in the United Kingdom has a single mutation from N501 to Y501 within the receptor binding domain (Y501-RBD), of the Spike protein of the virus. This variant is much more contagious than the original version (N501-RBD). We found that this mutated version of RBD binds to human Angiotensin Converting Enzyme 2 (ACE2) a ~10 times more tightly than the native version (N501-RBD). Modeling analysis showed that the N501Y mutation would allow a potential aromatic ring-ring interaction and an additional hydrogen bond between the RBD and ACE2. However, sera from individuals immunized with the Pfizer-BioNTech vaccine still efficiently block the binding of Y501-RBD to ACE2 though with a slight compromised manner by comparison with their ability to inhibit binding to ACE2 of N501-RBD. This may raise the concern whether therapeutic anti-RBD antibodies used to treat COVID-19 patients are still efficacious. Nevertheless, a therapeutic antibody, Bamlanivimab, still binds to the Y501-RBD as efficiently as its binds to N501-RBD. UR - https://www.unboundmedicine.com/medline/citation/33564771/The_basis_of_a_more_contagious_501Y_V1_variant_of_SARS_COV_2_ L2 - https://doi.org/10.1101/2021.02.02.428884 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.